Ondine Biomedical CEO, Carolyn Cross
In the United States, more than one million patients require mechanical ventilation annually, and 10% to 25% of those patients will develop VAP.
Vancouver, British Columbia (PRWEB) June 02, 2011
Ondine Biomedical Inc (TSX: OBP; AIM: OBP; the “Company”), a company dedicated to the development of photodisinfection-based products, today announced that the results of a study involving the company’s work with Photodynamic Therapy (PDT) has been presented at the 13th International Photodynamic Association World Congress in Innsbruck, Austria. The study demonstrates the effectiveness of antimicrobial PDT (aPDT), also known as photodisinfection, to eradicate antibiotic resistant biofilms from endotracheal tubes.
Ventilator-associated pneumonia (VAP) is the number one cause of healthcare-associated infections in intensive care unit patients. In the United States, more than one million patients require mechanical ventilation annually, and 10% to 25% of those patients will develop VAP. The study examined the use of non-invasive aPDT treatment to eradicate bacterial biofilms from the inner surface of endotracheal tubes. In the in vitro study, it was found that after one treatment of aPDT, polymicrobial biofilm was reduced by >99.9%. The ex vivo study showed that after one treatment of aPDT, 65% of the endotracheal tubes treated were completely eradicated of pathogenic bacteria, and an additional 15% showed a significant reduction.
This study demonstrated that aPDT can effectively treat antibiotic resistant biofilms in endotracheal tubes. The FDA has recently approved Ondine’s human clinical study to investigate the use of photodisinfection as a means to prevent VAP.
The following abstract was presented:
Abstract: O183
Reduction Of Endotracheal Tube Biofilms Using Antimicrobial Photodynamic Therapy
M Biel et al., Ondine Biomedical Inc.
About Ondine Biomedical Inc.
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA. For additional information, please visit the Company's website at: http://www.ondinebio.com.
Forward-Looking Statements:
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For further information please contact:
Carolyn Cross, Chairman and CEO
Ondine Biomedical Inc.
ccross(at)ondinebio(dot)com
Canaccord Genuity Limited, Nominated Adviser
Mark Williams/Bhavesh Patel
+4420 7050 6500
# # #
